A concentrated preparation of an ordinary food legume, sold as a seed-coat product standardized to two plant pigments or as a protein isolate. Only one small controlled trial in middle-aged adults tested any of it, using a protein drink; the seed-coat products on sale have never been tested in people. Allergy to legumes or birch pollen is the clearest risk. (Full Review)
| Marker | Target | Why |
|---|---|---|
| Fasting glucose | 75–86 mg/dL | Tracks the primary claimed metabolic effect |
| Fasting insulin | 2–5 µIU/mL | Detects insulin resistance before glucose rises |
| HbA1c | 4.8–5.2% | Confirms whether a glucose change persists |
| ALT | 10–26 U/L (men), 9–22 U/L (women) | Tests the liver-fat protection seen in mice |
| Non-HDL cholesterol | Below 100 mg/dL | Tests the cholesterol claim from animal studies |
| hs-CRP | Below 0.5 mg/L | Tracks the anti-inflammatory signal |
| Specific IgE: mung bean, soy, birch | Presence or absence, not a number | Identifies the at-risk population before exposure |
| Serum ferritin and plasma zinc | Ferritin 50–125 ng/mL; zinc 90–120 µg/dL | Detects mineral depletion from phytate |
| Tacrolimus or ciclosporin trough | Target set by the transplant team | Detects the reported drug-level interference |
Cadence: Baseline, 8 to 12 weeks after starting, then every 6 months. Transplant recipients: immunosuppressant levels at baseline, 1 week and 4 weeks after any change.